Plasma, the straw-colored liquid that makes up roughly half your blood volume, carries a cargo of proteins, clotting factors, and antibodies that modern medicine has learned to harvest for dozens of therapeutic purposes. You might need it whole, transfused directly to replace what you’ve lost in a trauma, or you might need just one of its components, isolated and concentrated in a factory. The range of conditions treated with plasma-derived therapies runs from massive hemorrhage to rare immune deficiencies to chronic joint pain, and understanding how each use works helps make sense of why donated plasma remains one of the most in-demand biological materials in health care.
When You Are Bleeding Faster Than Your Body Can Cope
The most urgent reason to receive plasma is severe, life-threatening bleeding. If you’re in a major car accident, undergo complex surgery, or suffer a gunshot wound, you can lose so much blood so quickly that your remaining blood loses the ability to clot properly. Red blood cell transfusions restore your oxygen-carrying capacity, but they don’t replace the clotting proteins you’ve also lost. Fresh frozen plasma fills that gap. It’s thawed and infused alongside red blood cells to keep the clotting system functional while surgeons work to stop the source of the bleeding.
Trauma resuscitation guidelines have shifted over the past two decades toward giving plasma earlier and in larger quantities relative to red blood cells. Current protocols advocate a ratio close to one unit of plasma for every unit of red blood cells in patients with severe injuries. A large study of blunt-trauma patients found that a higher plasma-to-red-blood-cell ratio was associated with lower in-hospital mortality, with roughly a quarter reduction in the odds of dying compared to a lower ratio, though the benefit appeared to plateau past a certain point rather than continuing to improve with ever more plasma.
1JAMA Surgery. High Fresh Frozen Plasma to Red Blood Cell Ratio and Survival Outcomes in Blunt TraumaThe traditional approach was more conservative: check lab results first, confirm the patient’s clotting is abnormal, and only then give plasma. The problem is that by the time the lab results come back showing a clotting deficit, the patient may already be in deep trouble. That older model often meant plasma arrived too late, when dilutional coagulopathy had already set in.
2PubMed Central. Clinical review: Fresh frozen plasma in massive bleedings – more questions than answersInherited Clotting Disorders Like Hemophilia
Some people don’t bleed because of trauma but because their bodies never made enough of a particular clotting factor. Hemophilia A, the most common severe form, results from a shortage of clotting factor VIII. Without treatment, a person with severe hemophilia can bleed spontaneously into joints, muscles, and organs. One of the oldest and still-used approaches is infusing a concentrate of factor VIII derived from pooled donor plasma.
These plasma-derived factor VIII products have been studied for decades. One of the longest-running real-world studies tracked nearly 200 hemophilia A patients across Germany and Hungary over 18 years, encompassing more than 1,400 patient-years of treatment. The results confirmed that the plasma-derived concentrate was effective and well tolerated across all age groups, from infants to adults in their eighties. Patients on a regular preventive schedule had far fewer bleeding episodes per year than those who treated bleeds only as they occurred.
3PubMed. Long-Term Safety and Efficacy Data of a Plasma-Derived Factor VIII Concentrate with von Willebrand Factor for Treatment of Patients with Hemophilia A Covering 18 YearsSynthetic (recombinant) versions of factor VIII also exist, and the choice between plasma-derived and recombinant products is an active area of debate in hematology. A cost analysis based on the SIPPET trial data found that starting treatment with a plasma-derived factor VIII containing von Willebrand factor could reduce costs by about a third compared to recombinant factor VIII in previously untreated patients with severe hemophilia A.
4PubMed. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United StatesBoosting a Failing Immune System
Your blood plasma is packed with immunoglobulin G (IgG), the antibodies your immune system has accumulated over a lifetime of fighting off infections. Some people are born with conditions that prevent them from producing enough of these antibodies on their own. Others lose the ability later in life, sometimes as a side effect of cancer treatment or organ transplantation. For these patients, intravenous immunoglobulin, known as IVIG, can be lifesaving.
IVIG is manufactured by pooling plasma from thousands of healthy donors, which ensures a broad repertoire of antibodies. It has been a standard treatment for more than two decades in conditions like X-linked agammaglobulinemia, common variable immunodeficiency, severe combined immunodeficiency, and Wiskott-Aldrich syndrome. Beyond simply replacing missing antibodies, IVIG also appears to have broader immune-modulating effects, which is why it gets prescribed for certain autoimmune and inflammatory conditions as well.
5PubMed Central. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapyOne well-known example is Guillain-Barré syndrome, a condition in which the immune system attacks peripheral nerves, causing weakness that can progress to paralysis. A standard initial course of IVIG is a first-line treatment. Research into whether giving a second course helps patients with a poor prognosis found no significant benefit from the extra infusion, suggesting there’s a ceiling to how much the treatment can do once the initial course has been administered.
6Journal of Neurology, Neurosurgery & Psychiatry. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID studyConvalescent Plasma for Infectious Diseases
The idea of borrowing antibodies from someone who has recovered from an infection dates back more than a century. Convalescent plasma therapy works on a straightforward principle: a recovered patient’s plasma contains antibodies that can neutralize the pathogen in a newly infected person. Those antibodies work by blocking surface proteins the virus needs to enter cells, preventing viral fusion, and interfering with the release of new viral particles.
7PubMed Central. Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19The approach has been tried across many outbreaks, from SARS to influenza to MERS. During the COVID-19 pandemic, it became one of the earliest experimental treatments tried at scale. But the results were mixed. Beyond direct viral neutralization, convalescent plasma may help by calming an overactive immune response, including the dangerous inflammatory cascade sometimes called a cytokine storm, and by modulating the blood’s tendency to form clots during severe infection.
8PubMed Central. Convalescent plasma in Covid-19: Possible mechanisms of actionThe critical lesson from COVID-19 was that timing matters enormously. Early observational studies were uncontrolled, used varying doses and schedules, and produced inconsistent results. A randomized controlled trial ultimately showed no benefit for patients who were already severely ill. The consensus that emerged was that convalescent plasma likely works best, if at all, when given early and to patients who are not yet critically ill.
9PubMed Central. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19Albumin for Liver Disease, Burns, and Critical Illness
Albumin is the most abundant protein in plasma, and it does a lot of quiet work: maintaining blood volume by keeping fluid in the bloodstream, transporting hormones and drugs, and acting as an antioxidant. When your liver is severely damaged by cirrhosis, it can’t make enough albumin, and fluid leaks out of the bloodstream into your abdomen, a condition called ascites. Draining that fluid through a large needle (paracentesis) provides relief, but the sudden shift in pressure can cause dangerous circulatory problems afterward.
Infusing albumin during or after large-volume paracentesis helps prevent that complication. A meta-analysis of randomized trials found that albumin reduced the incidence of post-procedure circulatory dysfunction compared with alternative treatments, and mortality was also lower in patients receiving albumin.
10PubMed. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trialsAlbumin also plays a role in burn care, where massive fluid resuscitation is needed to prevent shock. The evidence here is more nuanced. One meta-analysis of controlled clinical studies found that albumin infusion during the first 24 hours after a burn was associated with reduced mortality and less compartment syndrome after excluding studies at high risk of bias.
11PubMed Central. Albumin in Burn Shock Resuscitation: A Meta-Analysis of Controlled Clinical StudiesHowever, a separate systematic review of burn resuscitation reached a more cautious conclusion, finding no significant mortality benefit from albumin, though it did note that patients receiving albumin needed less total fluid during resuscitation.
12PubMed. Albumin administration for fluid resuscitation in burn patients: A systematic review and meta-analysisThe discrepancy between these two analyses likely reflects differences in which studies were included, how bias was handled, and when during the burn resuscitation albumin was given. In practice, many burn centers do use albumin-containing fluids, especially for larger burns, while acknowledging that the evidence isn’t fully settled.
Plasma Exchange for Autoimmune Diseases
Sometimes the problem isn’t that your blood is missing something but that it contains something harmful. In certain autoimmune diseases, rogue antibodies attack your own tissues. Plasma exchange, also called plasmapheresis, physically removes your plasma along with those damaging antibodies, and replaces it with donor plasma or an albumin solution. Think of it as an aggressive filter for your bloodstream.
One of the clearest examples is acquired thrombotic thrombocytopenic purpura, or TTP, a rare condition where abnormal blood clots form in small vessels throughout the body, destroying red blood cells and consuming platelets. Therapeutic plasma exchange is a cornerstone of treatment. In one study of 16 TTP patients treated with plasma exchange, three out of four improved, with platelet counts and hemoglobin levels rising significantly after treatment.
13PubMed Central. The Efficacy and Safety of Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic PurpuraCurrent standard of care for TTP now combines plasma exchange with immunosuppressive drugs and caplacizumab, a newer agent that targets von Willebrand factor.
14Journal of Thrombosis and Haemostasis. Management of acquired thrombotic thrombocytopenic purpura without plasma exchangePlasma exchange is also used in kidney-targeting autoimmune diseases. In anti-glomerular basement membrane disease (Goodpasture syndrome), antibodies attack the lining of the kidneys and sometimes the lungs.
15PubMed. Anti-glomerular basement membrane vasculitisIn ANCA-associated vasculitis, another condition that can destroy kidney function, plasmapheresis has been used as a rescue therapy when standard immunosuppression isn’t enough. One single-center study found that kidney function significantly improved six months after initiating plasma exchange, reaching levels comparable to patients who responded to initial treatment alone.
16PubMed. Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppressionCryoprecipitate and Fibrinogen Replacement
Fresh frozen plasma is a relatively blunt instrument. When a patient specifically needs fibrinogen, the protein that forms the structural scaffold of blood clots, clinicians can turn to cryoprecipitate. This is a concentrated plasma product made by slowly thawing frozen plasma and collecting the cold-insoluble proteins that precipitate out. The result is a smaller-volume product rich in fibrinogen, factor VIII, factor XIII, and von Willebrand factor.
Cryoprecipitate is widely used during surgeries and obstetric emergencies where fibrinogen levels drop dangerously low. Because it’s a pooled product containing a spectrum of coagulation factors beyond just fibrinogen, there’s ongoing debate about whether purified fibrinogen concentrate might be preferable in some situations, since the extra factors in cryoprecipitate could either help (by providing additional clotting support) or potentially cause problems (by tipping the balance toward excessive clotting).
17PubMed. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate?How Donated Plasma Becomes Medicine
The process of turning raw donated plasma into therapeutic products is called fractionation, and it’s been built on essentially the same foundation since the 1940s. The core technique uses chilled ethanol at varying concentrations to precipitate out different protein groups from plasma. Over the decades, manufacturers have added steps to improve purity, increase the yield of immunoglobulin, and isolate newer products like alpha-1 protease inhibitor and protein C.
18PubMed Central. Modern plasma fractionationSafety against blood-borne viruses is the paramount concern. A full chain of measures has been layered into the manufacturing process, including dedicated viral inactivation steps such as heat treatment and solvent-detergent processing, along with filtration methods that physically remove viral particles. Plasma pools are tested for HIV, hepatitis B, hepatitis C, hepatitis A, and parvovirus B19 before processing begins.
19PubMed. Viral safety of recovered plasma for contract fractionation; an Iranian experience, 2006-2015Despite the emergence of many alternative manufacturing technologies over the years, the ethanol-based fractionation method, combined with modern upstream harvesting and downstream virus-safety steps, remains the global industry standard.
20PubMed. The past, present and future of blood plasma fractionationPlatelet-Rich Plasma for Joint Pain
Not all plasma therapies involve transfusion or fractionation. Platelet-rich plasma, or PRP, uses your own blood. A small sample is drawn, spun in a centrifuge to concentrate the platelets and their growth factors, and then injected into a damaged joint or tendon. The theory is that this concentrated cocktail of growth factors accelerates tissue repair and reduces inflammation.
PRP has become popular for treating osteoarthritis, particularly in knees and hips. A retrospective study of PRP injections for large-joint osteoarthritis found clinically meaningful improvements in both pain and function: pain scores improved by about 49% at six months and 45% at twelve months, while function scores improved by roughly 44% at six months and 39% at twelve months.
21PubMed Central. Platelet-rich plasma treatment for large joint osteoarthritis: retrospective study highlighting a possible treatment protocol with long-lasting stimulation of the joint with an adequate dose of plateletsPRP occupies a somewhat gray zone in medicine. Many orthopedic surgeons offer it, and many patients report feeling better, but high-quality randomized trials have produced uneven results depending on the joint involved, the severity of the arthritis, and the specific PRP preparation used. Insurance coverage varies widely because regulatory bodies in many countries haven’t classified PRP as a standard treatment for osteoarthritis. Still, for people who haven’t responded to conventional treatments and aren’t ready for joint replacement, it’s a reasonable option to discuss with a specialist.
Plasma Therapy in Veterinary Medicine
Humans aren’t the only patients who benefit from plasma. In equine medicine, plasma transfusion is a well-established treatment for newborn foals. Unlike human babies, foals are born with virtually no circulating antibodies; they absorb them from the mare’s first milk (colostrum) in the first hours of life. If that transfer fails, a condition called failure of transfer of passive immunity leaves the foal dangerously vulnerable to infection. A plasma transfusion can deliver the immunoglobulin G the foal didn’t get from its mother.
22PubMed. Effect of plasma transfusion on serum amyloid A concentration in healthy neonatal foals and foals with failure of transfer of passive immunityOn some breeding farms, plasma is also given preventively to foals at risk for infections like Rhodococcus equi pneumonia, even when their immunoglobulin levels are adequate. The principle is the same one that underlies IVIG in humans: supplement the antibody supply before an infection can take hold.
Cold Atmospheric Plasma Is a Different Thing Entirely
If you search for plasma therapy, you’ll eventually run into articles about cold atmospheric plasma, or CAP. This isn’t blood plasma. It’s ionized gas, a stream of reactive particles generated by running a gas through an electric field at close to room temperature. Confusingly, the word “plasma” covers both the liquid component of blood and the fourth state of matter, and both have medical uses.
CAP devices look a bit like small pens or wands that blow a faintly glowing stream of gas onto tissue. In wound care, they’ve shown genuine promise. A multicenter randomized trial found that chronic wounds treated with a cold plasma jet healed significantly faster than those treated with standard wound dressings alone: complete healing within six weeks was documented in about 59% of CAP-treated patients compared to roughly 5% of those receiving best-practice dressings alone.
23Scientific Reports. Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trialAnother multicenter trial confirmed that adding cold plasma therapy to standard wound treatment accelerated wound closure and cut antibiotic use: only 4% of patients in the plasma group needed antibiotics, versus 23% in the standard-treatment-only group.
24PubMed Central. Cold Plasma Therapy in Chronic Wounds—A Multicenter, Randomized Controlled Clinical Trial (Plasma on Chronic Wounds for Epidermal Regeneration Study): Preliminary ResultsCAP has also attracted attention as a possible anti-cancer tool. The reactive oxygen and nitrogen species it generates can trigger cancer cell death while leaving healthy cells relatively unharmed, at least in laboratory settings.
25PubMed Central. Cold atmospheric plasma, a novel promising anti-cancer treatment modalityEarly-stage research continues to explore how this selectivity works and whether it can translate into clinical cancer treatment, but the technology remains largely experimental for oncology.
26Bioactive Materials. Advances in cold atmospheric plasma therapy for cancerFor wound care, particularly chronic ulcers and bedsores in hospital settings, CAP is closer to routine clinical use and offers a potential way to reduce reliance on antibiotics at a time when antimicrobial resistance is a growing concern.
27PubMed Central. The Role of Cold Atmospheric Plasma in Wound Healing Processes in Critically Ill Patients